ArticleLiver cancer2024

Nivolumab plus Ipilimumab: A Novel First-Line Combination Immunotherapy for Unresectable Hepatocellular Carcinoma.

Masatoshi KudoPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.